Ipamorelin — Wolverine Health

How it works

A selective GH secretagogue that binds the ghrelin receptor (GHSR-1a) to stimulate pituitary GH release. Its clinical edge over older GHRPs: it doesn't significantly raise cortisol or prolactin. Animal studies show it increases GH and IGF-1 without the cortisol spike that limits GHRP-6 utility. Human trials are limited. The clean hormonal profile is the main draw — nobody's proven it outperforms competitors in humans.

FDA status: No FDA approval. Not on the PCAC July 2026 review docket.
WADA status: Permitted in sport
Route: subcutaneous injection

Key studies

Ipamorelin, the first selective growth hormone secretagogue — Raun et al. (1998)

Ipamorelin is a selective growth hormone secretagogue that stimulates GH release with minimal effect on cortisol and prolactin compared with GHRP-6 in conscious swine.

Wolverine Health is building physician-supervised peptide protocols. Get early access.

Join the waitlist

Research on Ipamorelin

Peptide access by US state: why the regulatory patchwork right now is real

The federal compounding framework applies the same way in every state. The state pharmacy boards do not. The result is a real state-by-state patchwork that decides whether a telehealth prescription for a compounded peptide is actually fillable where you live.

What RFK Jr.'s February 2026 announcement actually said about peptides

The "announcement" was a Joe Rogan appearance, not a Federal Register notice. The wellness scene heard one thing. The actual signal was narrower, and the rulemaking that turns it into access is still more than a year away.

Growth hormone secretagogues: what they are and why four peptides keep showing up together

WADA

CJC-1295, ipamorelin, sermorelin, and tesamorelin all sit in the growth-hormone-secretagogue class. They are routinely confused for each other. Here is the mechanism, the human evidence on each, and the four separate regulatory files behind the shared label.

CJC-1295 vs ipamorelin: which half of the GHRH stack has the deeper evidence file?

WADA

CJC-1295 and ipamorelin get sold side-by-side as the growth-hormone protocol — one lifts the baseline, the other adds the pulse. Two molecules, two different mechanisms, two human evidence files that almost don't overlap. Here is what the published data actually separates them on.

Ipamorelin: the quietest growth hormone secretagogue

WADA

Ipamorelin's selling point is what it doesn't do — no cortisol spike, no prolactin spike, just a clean ghrelin-receptor GH pulse. Here's what the animal work actually shows, why the one Phase 2 trial was null, and what that means for the stack marketing.

Ipamorelin: Growth Hormone Secretagogue Mechanism and Research Overview

WADA

An independent science-journalism review of ipamorelin research — how this selective GH secretagogue works, what the preclinical and limited clinical literature shows, and its current regulatory standing.